secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corvus Pharmaceuticals, Inc. (CRVS)
CIK:        0001626971
Form:       8-K
Filed at:   2026-05-14T11:01:18+00:00
Accession:  0001171843-26-003397
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corvus reports positive Phase 1 soquelitinib data in atopic dermatitis; durable remissions without rebound
--------------------------------------------------------------------------------

- 72-patient Phase 1 trial met safety and efficacy endpoints; no severe adverse events.
- Cohort 4 (200 mg BID for 56 days): 75% achieved EASI 75, 25% achieved EASI 90, 33% IGA 0/1.
- Biomarker data confirms ITK inhibition reduces Th2/Th17 cytokines and increases persistent Tregs.
- Drug-free remission maintained in post-treatment follow-up (up to 90 days) with no disease rebound.
- SIERRA1 Phase 2 trial for moderate-to-severe atopic dermatitis now enrolling ~200 patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626971/000117184326003397/0001171843-26-003397-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626971/000117184326003397/f8k_051426.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-003397

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer